Press

Ovoclone has received extensive media coverage in press, radio, and television, both nationally and internationally, for its work in animal cloning and reproductive biotechnology in Spain.

As a specialized center based in Marbella, our scientific activity has generated significant media interest, particularly in the fields of pet cloning, high-value genetic horses, and cell line preservation.

Our continued presence in the media reflects the relevance of the project, the technological impact of our research, and the consolidation of Ovoclone as a leading reference in animal cloning in Spain.

In this section, we compile some of the main publications, interviews, and reports dedicated to our activity.

Image of a reporter filming in the Ovoclone laboratory

The union between science and ethics drives the progress of cloning in Spain, strengthening its position in advanced biotechnology.

Ovoclone strengthens the role of reproductive biotechnology with pioneering cell replication techniques.

Spain is leading a new era in reproductive science with cutting-edge cloning projects.

Ovoclone, the pioneering Spanish laboratory in Europe specialised in pet cloning, operates under current regulations and with ethical backing.

Ovoclone, the pioneering Spanish laboratory in Europe specialised in pet cloning, operates under current regulations and with ethical backing.

The first canine clone of 2025 marks a new milestone in animal biotechnology, demonstrating advances in preservation and cloning techniques.

Ovoclone welcomes 2025 with the birth of the first cloned dog and looks forward to a year full of success in animal replication.

The first clone of 2025 marks a milestone in animal biotechnology. Ovoclone leads this breakthrough, promising a key year for cloning and genetic innovation.

The companies Ovohorse and Ovoclone, part of the Ovo Group, received the European Awards in Medicine 2024 in the Genetics category.

Thanks to technological advances, innovations, and the research work carried out by the team in Ovohorse’s laboratories on animal cloning and cell line preservation.

A laboratory in Marbella, Málaga, will be a pioneer in Europe in cloning legendary deceased horses.

From Marbella, a laboratory in Málaga is leading the way in Europe in cloning legendary horses that marked the history of the equestrian world.

Animal cloning can be carried out in Málaga, at Spain’s first and only laboratory.

Animal cloning is already a reality in Málaga, home to Spain’s first and only laboratory specialised in this technique.

Leave us your details so we can contact you and provide you with all the information about your kit.

Data Controller: OVOHORSE IBERICA S.L | Purpose: To provide the information or services you request from us. | Legal Basis: Consent of the data subject | Recipients: Data will not be transferred to third parties except under legal obligation. | Rights: To access, rectify and delete data, as well as other rights, as explained in the additional information. | You can consult the additional and detailed information in our Privacy Policy section.

Leave us your details so we can contact you and provide all the information about our clones.

Data Controller: OVOHORSE IBERICA S.L | Purpose: To provide the information or services you request from us. | Legal Basis: Consent of the data subject | Recipients: Data will not be transferred to third parties except under legal obligation. | Rights: To access, rectify and delete data, as well as other rights, as explained in the additional information. | You can consult the additional and detailed information in our Privacy Policy section.

Data Controller: OVOHORSE IBERICA S.L | Purpose: To provide the information or services you request from us. | Legal Basis: Consent of the data subject | Recipients: Data will not be transferred to third parties except under legal obligation. | Rights: To access, rectify and delete data, as well as other rights, as explained in the additional information. | You can consult the additional and detailed information in our Privacy Policy section.